Des vaccins COVID-19 à ARNm pourraient aider à lutter contre le cancer
COVID-19 vaccines, particularly mRNA vaccines like Pfizer and Moderna, may offer an unexpected benefit to cancer patients. Recent research suggests they may boost the immune system to better fight tumors.
Dr. Adam Grippin of MD Anderson Cancer Center explains, "We studied over 1,000 lung cancer and melanoma patients treated with immunotherapy. We found that those who received an mRNA vaccine at the beginning of their treatment lived significantly longer than those who did not."
The results reveal that a Pfizer or Moderna vaccine administered within 100 days of starting treatment significantly increases survival rates, particularly in patients with advanced lung or skin cancer.
A lead for new therapies
Another specialist points out: "These data are very promising, as they suggest that these vaccines could help the body better defend itself against cancer." However, he specifies that these results still need to be confirmed in more comprehensive clinical trials before any use in routine medicine.
A study of nearly 1,000 patients shows that those vaccinated against COVID-19 are almost twice as likely to be alive three years after treatment.
Dr. Grippin concludes: “The current vaccine could not only strengthen the immune response, but also pave the way for new, more effective RNA-based therapies for those who do not respond to conventional treatments.”
Unlike traditional vaccines such as those against influenza, mRNA-based vaccines now offer a new perspective in the fight against cancer.
Commentaires (3)
Piste à creuser
N importe quoi?
Laa ilaaha illa'Allah ! Cette article même est un crime. Même s'il n'a dit que "pourrait ".
Participer à la Discussion